BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 1184967)

  • 1. Cyanate as an inactivator of complement proteins.
    Schultz DR; Arnold PI
    J Immunol; 1975 Dec; 115(6):1558-65. PubMed ID: 1184967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum lipoproteins and C567-INH activity.
    Lint TF; Behrends CL; Gewurz H
    J Immunol; 1977 Sep; 119(3):883-8. PubMed ID: 561124
    [No Abstract]   [Full Text] [Related]  

  • 3. Inhibition of immune haemolysis by a serum factor found in C3-deficient subjects.
    Kitamura H; Tsuboi M
    Immunology; 1989 Feb; 66(2):264-9. PubMed ID: 2925225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced reactive lysis of paroxysmal nocturnal hemoglobinuria erythrocytes by C5b-9 does not involve increased C7 binding or cell-bound C3b.
    Rosenfeld SI; Jenkins DE; Leddy JP
    J Immunol; 1985 Jan; 134(1):506-11. PubMed ID: 3964820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of the fifth and sixth component of the complement system: similarities between C5b6 and C(56)a with respect to lytic enhancement by cell-bound C3b or A2C, and species preferences of target cell.
    Hänsch GM; Hammer CH; Mayer MM; Shin ML
    J Immunol; 1981 Sep; 127(3):999-1002. PubMed ID: 6911149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C3-independent immune haemolysis: mechanism of membrane attack complex formation.
    Kitamura H; Tsuboi M; Nagaki K
    Immunology; 1986 Sep; 59(1):147-51. PubMed ID: 3759127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies on rat complement. I. Immune adherence and immune hemolysis activities of rat serum.
    Sakamoto M
    Jpn J Exp Med; 1975 Jun; 45(3):183-9. PubMed ID: 1177359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humoral immunostimulation. IV. Role of complement.
    Shearer WT; Atkinson JP; Frank MM; Parker CW
    J Exp Med; 1975 Apr; 141(4):736-52. PubMed ID: 1168690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trypsin-activated complex of human factor B with cobra venom factor (CVF), cleaving C3 and C5 and generating a lytic factor for unsensitized guinea pig erythrocytes. I. Generation of the activated complex.
    Miyama A; Kato T; Horai S; Yokoo J; Kashiba S
    Biken J; 1975 Dec; 18(4):193-204. PubMed ID: 1218074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human peritoneal macrophages. Production in vitro of the active terminal complement components C5 to C9 and a functional alternative pathway of complement. Brief report.
    Hetland G; Bungum L
    APMIS; 1988 Jan; 96(1):89-92. PubMed ID: 3345254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.
    Ollert MW; Kadlec JV; Petrella EC; Bredehorst R; Vogel CW
    Cancer Res; 1993 Feb; 53(3):592-9. PubMed ID: 8425193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies on the mechanism of bacterial resistance to complement-mediated killing. VI. IgG increases the bactericidal efficiency of C5b-9 for E. coli 0111B4 by acting at a step before C5 cleavage.
    Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM
    J Immunol; 1983 Nov; 131(5):2570-5. PubMed ID: 6355297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C3-independent immune haemolysis: haemolysis of EAC14oxy2 cells by C5-C9 without participation of C3.
    Kitamura H; Matsumoto M; Nagaki K
    Immunology; 1984 Nov; 53(3):575-82. PubMed ID: 6237987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testing of hemolytic complement components in domestic animals.
    Barta O; Hubbert NL
    Am J Vet Res; 1978 Aug; 39(8):1303-8. PubMed ID: 697137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of immune precipitation by complement.
    Hong K; Takata Y; Sayama K; Kozono H; Takeda J; Nakano Y; Kinoshita T; Inoue K
    J Immunol; 1984 Sep; 133(3):1464-70. PubMed ID: 6747294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Control of C1 activation by nascent C3b and C4b: a mechanism of feedback inhibition.
    Ziccardi RJ
    J Immunol; 1986 May; 136(9):3378-83. PubMed ID: 3485688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies in vivo and in vitro on an abnormality in the metabolism of C3 in a patient with increased susceptibility to infection.
    Alper CA; Abramson N; Johnston RB; Jandl JH; Rosen FS
    J Clin Invest; 1970 Nov; 49(11):1975-85. PubMed ID: 4097977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonimmunologic complement activation in normal human serum induced by radiographic contrast media.
    Kolb WP; Lang JH; Lasser EC
    J Immunol; 1978 Oct; 121(4):1232-8. PubMed ID: 100552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The C5b-6 complex: reaction with C7, C8, C9.
    Podack ER; Biesecker G; Kolb WP; Müller-Eberhard HJ
    J Immunol; 1978 Aug; 121(2):484-90. PubMed ID: 681745
    [No Abstract]   [Full Text] [Related]  

  • 20. The activation of C5 in the fluid phase and in the absence of C3 through the classical pathway of the complement system.
    Kitamura H; Tsuboi M; Nagaki K
    Immunology; 1986 Jul; 58(3):459-65. PubMed ID: 3733147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.